Merlise achieves breakthrough results on SciFact-Open
Merlise
Financial · Teardown

Ten days after filing, a fifth of the revenue disappeared

May 20264 min read

NeuroOne Medical Technologies filed its 10-Q for the first quarter of fiscal 2026 on May 12, reporting 2.4 million dollars in revenue. On May 22, the company told investors that roughly half a million of that figure should not have been recognized, tied to a customer order modified right at quarter end. A twenty one percent gap. The company found it and disclosed it within six days.

The filing said 2.4 million on revenue. The company's own correction said otherwise, ten days later.

An honest company, a real gap

This is not a story about wrongdoing. NeuroOne found the problem during its own management review and told the market quickly. That speed is worth stating plainly, because running this filing through Merlise has one purpose: showing what a same day read of the original filing would have surfaced, before the correction became necessary.

The original 10-Q already contained the tool needed to catch its own error: a footnote describing the company's revenue recognition policy. The order modification at quarter end did not clearly meet the criteria that footnote lays out. The filing, read against itself, already carried the seed of the problem.

Reading a number against its own policy

Before anyone, including NeuroOne itself, knew the filing needed correcting, we ran the May 12 10-Q exactly as it stood. Merlise matched the reported revenue figure against the recognition policy sitting in the filing's own footnotes, then flagged the gap between what that policy requires and what the quarter end order modification actually supported.

The result compares the company's own stated policy against the transaction the policy governs, surfaced at a confidence low enough to warrant review. Nothing here is dressed up to look more certain than it is, and nothing is presented as a settled conclusion.

A number with a history

A financial figure lives in three states worth tracking. What was originally filed. Whatever correction came later. Any downstream claim still resting on the old number, unaware anything changed. A green check on May 13 stops being a green check on May 23, and Merlise keeps that chain visible so a claim tied to an old filing gets flagged the moment the filing underneath it moves, instead of staying quietly wrong in a deck or a memo somewhere.

The evidence ledger

The same claim by claim view the product shows on a live document, built from this case.

VERIFICATION LEDGER10-Q, filed May 12, 2026 · 2 claims shown
Quarterly revenue of 2.4 million recognized for the period.Numeric
34%
Recognition criteria in the filing's own policy footnote not clearly met for the order modified at period end.Disputed
10-Q, filed May 12
Gross profit for the quarter as stated in the MD&A.Numeric
41%
Depends on the same disputed revenue figure above.Disputed
10-Q, filed May 12

How it resolves

Line items touched by the correction
Line itemAs filed May 12As corrected May 22
Revenue$2.4M$1.9M
Gross profitReportedRestated down
Cash positionUnaffectedUnaffected

The resolving record

NeuroOne's own May 22 press release and accompanying 8-K disclose the exact overstatement, its cause, and the corrected figures.

NeuroOne Medical Technologies, Form 8-K, May 22, 2026

The correction reduced reported quarterly revenue from 2.4 million to roughly 1.9 million, a twenty one percent restatement.